Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nicotine Lollipops Active Ingredient Nicotine Salicylate “Illegal” – FDA

This article was originally published in The Tan Sheet

Executive Summary

The Professional Compounding Centers of America is urging its members to switch from nicotine salicylate to nicotine polacrilex when compounding lollipops to help patients quit smoking
Advertisement

Related Content

Forty-Two AGs Weigh In: Ariva “Cigalett” Falls Under FDA Oversight
Forty-Two AGs Weigh In: Ariva “Cigalett” Falls Under FDA Oversight
Forty-Two AGs Weigh In: Ariva “Cigalett” Falls Under FDA Oversight
FDA Warning Letters Increasingly Targeting Internet Claims
FDA Warning Letters Increasingly Targeting Internet Claims
Nico Water Not Dietary Supplement Due To Active Drug Ingredient
Ariva “Cigalett” Sweeteners, Emulsifiers Make Product A Food – GSK
Nicotine letter
Nicotine Lollipops Require FDA Regulation, Advocacy Group Says
Nicotine Lollipops Require FDA Regulation, Advocacy Group Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS093887

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel